News

Vertex Plunges Around 24% in Six Months: How to Play the Stock

Vertex shares fall nearly 24% in six months on pipeline setbacks but strong CF sales and new launches may shape the future.

Why This Biotech Company Could Be a Growth Stock Powerhouse

This biotech is a leader in the treatment of cystic fibrosis, and that’s helped earnings explode higher over the years. The ...

Three scientists who revolutionized cystic fibrosis treatment win prestigious Lasker award

Their research led to the development of a drug that nearly doubles the life expectancy for adult cystic fibrosis patients.

Vertex Pharmaceuticals Incorporated: Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named as one of the winners of this year's Lasker~DeBakey Clinical Medical Researc ...

Vertex Scientists Awarded the 2025 Lasker~DeBakey Clinical Medical Research Award for Pioneering Discoveries in Cystic Fibrosis

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Senior Vice President Paul Negulescu has been named ...
Zacks Investment Research on MSN

Why Is Vertex (VRTX) Up 6.9% Since Last Earnings Report?

A month has gone by since the last earnings report for Vertex Pharmaceuticals (VRTX). Shares have added about 6.9% in that time frame, outperforming the S&P 500. But investors have to be wondering, ...